Biolegend, 502501, Purified anti-human IFN-γ Antibody, 50μg

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
50μg
Verified Reactivity: Human
Reported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Partially purified, native human IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: ICFC - Quality tested WB, ELISA - Verified
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µL volume. For Western blotting, the suggested use of this reagent is 0.5 - 2.0 µg per mL.For ELISA applications, the antibody should be titrated between 0.25 - 2 µg/mL to determine optimal condition. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody. Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ -producing cells within mixed cell populations. Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut) Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut) Sester M, et al. 2002. J. Virol. 76:3748. (ICFC) Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC) Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA) Chen H, et al. 2005. J. Immunol. 175:591. (ICFC) Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC) Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)
Product Citations: Olson BM, et al. 2017. Cancer Immunol Res. 5:1074. PubMed Law JC, et al. 2021. J Immunol. 206:37. PubMed Wang D, et al. 2022. Int J Oral Sci. 14:8. PubMed Alroqi F, et al. 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed Wang W, et al. 2018. Cancer Cell. 34:757. PubMed Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed Willing A, et al. 2018. J Immunol. 200:974. PubMed Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed Peeters MJW, et al. 2021. Front Immunol. 12:718863. PubMed Aravena O, et al. 2017. Arthritis Res Ther. 19:8. PubMed Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed Cribbs AP, et al. 2021. Front Immunol. 12:626255. PubMed Salerno F, et al. 2019. J Immunol. 202:714. PubMed Rodriguez-Salazar CA, et al. 2022. Viruses. 14:. PubMed Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed Park JB, et al. 2019. Mol Cells. 42:597. PubMed Li H, et al. 2020. Front Immunol. 11:1777. PubMed Kameda M, et al. 2020. PLoS One. 15:e0241719. PubMed Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed Macmillan ML, et al. 2021. Blood Adv. 5:1425. PubMed Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed Chang ZL, et al. 2018. Nat Chem Biol. 0.803472222. PubMed Sordo-Bahamonde C, et al. 2021. Cancers (Basel). 13:. PubMed Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed Iwamoto S, et al. 2007. J Immunol. 179:1449. PubMed Pompura SL, et al. 2021. J Clin Invest. 131:. PubMed Stensland ZC, et al. 2022. iScience. 25:103626. PubMed Mou W, et al. 2017. BMC Immunol. 18:36. PubMed Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed
RRID: AB_315226 (BioLegend Cat. No. 502501) AB_315227 (BioLegend Cat. No. 502502)
Structure: Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID: 3458
UniProt: View information about IFN-gamma on UniProt.org
Clone: 4S.B3
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype: Mouse IgG1, κ